Results 61 to 70 of about 5,265 (145)

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.

, 2016
PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials [PDF]

, 2017
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir ...
Eric Lawitz, Feld, JJ, Graham R. Foster, Bernard E. Willems, Norbert Bräu, Pearlman, B, Peter J. Ruane, Ira M. Jacobson, Robert H. Hyland, Tarik Asselah, Ronald G. Nahass, Dvory-Sobol, H, Jordan J. Feld, Shafran, SD, Thompson, AJ, Stamm, LM, Zhu, Y, Thomas Berg, Svarovskaia, E, Brainard, DM, Bräu, N, Berg, T, Asselah, T, Willems, BE, McHutchison, JG, Workowski, KA, Kosh Agarwal, Lawitz, E, Stephen D. Shafran, Brian Pearlman, Diana M. Brainard, G. Mani Subramanian, Stuart K. Roberts, Stedman, CAM, Dore, GJ, John G. McHutchison, Nahass, RG, Hadas Dvory-Sobol, Hyland, RH, Gane, EJ, Luisa M. Stamm, Catherine A.M. Stedman, Evguenia Svarovskaia, Jacobson, IM, Mitchell Davis, Agarwal, K, Bhandari, BR, Bal Raj Bhandari, Subramanian, GM, Borgia, SM, Roberts, SK, Alexander J. Thompson, Yanni Zhu, Ruane, PJ, Davis, M, Kimberly A. Workowski, Sergio M. Borgia, Gregory J. Dore, Dore, GJ ; https://orcid.org/, Foster, GR, Edward J. Gane   +60 more
core   +1 more source

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

, 2014
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir ...
Reddy, K. R., Shiffman, M. L., Schiff, E., Ghalib, R., Kowdley, K. V., Gordon, S. C., Rossaro, L., Bernstein, D. E., Lawitz, E., Fried, M. W., +15 additional authors, DI BISCEGLIE, Adrian M, MCHUTCHISON, John G, HERRING, Robert, MUIR, Andrew J, LAWITZ, Eric, SVAROVSKAIA, Evguenia, PANG, Phillip S, BERNSTEIN, David E, SCHIFF, Eugene, SHIFFMAN, Mitchell L, HYLAND, Robert H, CHOJKIER, Mario, POUND, David, RAJENDER REDDY, K, DI AN, D I, RYAN, Michael, SUBRAMANIAN, G. Mani, POCKROS, Paul J, ROSSARO, Lorenzo, GORDON, Stuart C, SYMONDS, William T, FRIED, Michael W, RUSTGI, Vinod, KOWDLEY, Kris V, GHALIB, Reem   +35 more
core   +1 more source

Human Pegivirus Encephalitis With Brain Detection and Response to Sofosbuvir Ledipasvir

Annals of Clinical and Translational Neurology, Volume 13, Issue 10, Page 2138-2142, October 2026.
ABSTRACT Human pegivirus (HPgV‐1) has been associated with severe encephalomyelitis in immunocompromised patients. Its neurological spectrum remains poorly defined. We report a slowly progressive encephalitis in a person living with well‐controlled HIV, characterized by white matter abnormalities and inflammatory cerebrospinal fluid (CSF). HPgV RNA was
Antoine Moulignier, Françoise Heran, Francis Lallemand, Pierre Bourdillon   +3 more
wiley   +1 more source

Persistent Hepatitis C Viremia Following Sofosbuvir/Velpatasvir During Bendamustine‐Rituximab Therapy for Follicular Lymphoma

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT This is a case of a 67‐year‐old female with follicular lymphoma who developed hepatitis C viremia during chemotherapy and failed treatment with a 12‐week course of sofosbuvir/velpatasvir. This highlights the possibility that chemotherapy may have contributed to failure to achieve sustained virologic response despite otherwise appropriate ...
Chisom J. Orakwue, Rade N. Pejic
wiley   +1 more source

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

, 2018
ObjectiveWe evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed ...
Aisha Elsharkawy, Reham Soliman, Gamal Esmat, Rabab Fouad, Sophia Lu, Wahid Doss, Talaat Zakareya, Mohamed Elbasiony, Kathryn Kersey, Imam Waked, Wael Abdel-Razek, Radi Hammad, Diana M Brainard, Benedetta Massetto, John G McHutchison, Mohamed Hassany, Anu Osinusi, Gamal Shiha   +17 more
core   +1 more source

Frequency of Metabolic Syndrome in Patients With Hepatitis C Virus Infection: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Metabolic syndrome significantly increases the risk of cardiovascular disease and type 2 diabetes. Hepatitis C virus (HCV) infection has been associated with an increased risk of metabolic syndrome. This study aims to explore this association to improve management strategies for HCV patients at risk of metabolic syndrome ...
Muhammad Awais, Maryam Ilyas, Muhammad Husnain Ahmad, Muhammad Taha Shaukat, Abdul Waheed, Aniqa Iqbal, Muhammad Umar Nadeem, Nimra Mahmood, Ali Gohar, Hamza Zaheer, Ahmed Zia, Masab Ali   +11 more
wiley   +1 more source

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

, 2015
As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.
Doehle, Brian, Schiff, Eugene, Fried, Michael, Bzowej, Natalie, An, Di, Curry, Michael P, Teperman, Lewis, Flamm, Steven L, McHutchison, John G, O'Leary, Jacqueline G, Fontana, Robert, Brown, Jr, Robert S, Fenkel, Jonathan M, Schiano, Thomas, Brainard, Diana M, Lawitz, Eric, ASTRAL-4 Investigators, Muir, Andrew J, Korenblat, Kevin M, McNally, John, Reddy, K Rajender, Osinusi, Anu, Charlton, Michael   +22 more
core   +1 more source

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

DIRECT ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH END STAGE KIDNEY DISEASE WITH ACUTE HCV INFECTION

Mediterranean Journal of Hematology and Infectious Diseases, 2019
Background: Hepatitis C virus (HCV) infection is a public health problem. Such an infection is prevalent and aggressive in patients with end-stage kidney disease (ESKD).
Nawfal R Hussein, Zana Saleem, Kais Abd
doaj   +1 more source